A new survey by SwedenBIO shows that Swedish life science companies are even more confident about future growth compared to pre-COVID. A similar report was published exactly one year ago
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
The COVID-19 pandemic
The company delays EU vaccine deliveries as US pauses use over blood clots. Johnson & Johnson is to pause deliveries of its single-shot COVID-19 vaccine in Europe pending an investigation
The most common long-term symptoms are a loss of smell and taste and fatigue, according to a study published in the journal JAMA, conducted by researchers at Danderyd Hospital and
The European Medicines Agency’s safety committee (PRAC) has concluded that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly COVID-19 Vaccine
Iconovo has signed an agreement with Immune System Regulation (ISR) for the development of an inhaled COVID-19 vaccine in Iconovo’s inhaler ICOone. The agreement is Iconovo’s second agreement within its
Valneva has announced positive data for Part A of the Phase 1/2 clinical trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. Based on this data, the company plans to
In patients with severe COVID-19, the innate immune system overreacts and this overreaction may underlie the formation of blood clots (thrombi) and deterioration in oxygen saturation that affect the patients,
NLS News
Immunicum has announced the initiation of a research collaboration with the laboratory of Nina Bhardwaj, Director of Immunotherapy and the Medical Director of the Vaccine and Cell Therapy Core Facility,
The companies have entered into a preclinical research collaboration agreement to evaluate the therapeutic potential of combining their two IgG-modulating technologies. The preclinical research collaboration is set up to explore
The company enters into an exclusive license agreement with the university for a class of new drug candidates and forms a strategic partnership with Aurelius Biotherapeutics. Lytix Biopharma, in collaboration
Genmab and Seagen have announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking accelerated approval for tisotumab vedotin. This
The Novo Nordisk Foundation has supported Danish life sciences for almost 100 years, maintaining knowledge, technology, talent and companies in the region. You can not really speak about life sciences
The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808. “FDA approval of the
AlgoDx has announced that all existing investors have committed to a follow-up investment summing up to 13 MSEK (approximately 1.25 MEUR). The round was led by Nascent Invest with participation
CDMO Recipharm has announced that its 2020 International Environmental Award will be presented to Amy Pruden, Professor of Civil and Environmental Engineering at Virginia Tech in Blacksburg, Virginia, US. Amy
Nanoform Finland and Nacuity Pharmaceuticals, a Texas-based clinical stage pharmaceutical company, have signed a Technology Proof of Concept agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle
Center for Translational Research Sweden AB (CTR) acquires Toxicology Knowledge Team Sweden AB (TKT) further strengthening the CTR group with optimized toxicological support. From April 1, TKT is a fully
The companies have announced data on the drug candidate lecanemab (BAN2401). The presentations included findings suggesting that lecanemab could be of potential benefit for adults with Down’s syndrome with signs
Researchers at VTT have developed light and wireless sensors capable of capturing respiration rate, oxygen saturation, heart rate, temperature and even an ECG. If it were possible to monitor the
Elekta will establish a permanent office in Cairo, Egypt, to address the shortage of radiotherapy delivery systems and software solutions that play an integral part in treating cancer and brain
We would like to thank our readers, subscribers and collaboration partners for a fruitful first quarter 2021, and we wish you all a relaxing – and safe – Easter! Nordic
Drug and device development
Ultimovacs will participate in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups
The companies have announced data on the drug candidate lecanemab (BAN2401). The presentations included findings suggesting that lecanemab could be of potential benefit for adults with Down’s syndrome with signs
The research results show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as
Gilead Sciences and Novo Nordisk have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy
Follicum announces that significant progress has been made in the company’s development of new drug treatments for diabetes and other diseases. Within the framework of a preclinical research project, the
Profile
What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company. Fascinated by the
In a new job
During 2020, the COVID-19 pandemic has caused many previously office-based employees to begin to work from home. Whilst working remotely is seen by some as a temporary measure, others suggest
The Board of Directors of the company has appointed Søren Bregenholt as new Chief Executive Officer (CEO). He is appointed to strengthen Alligator’s business development activities and clinical progress on
Kerstin Jakobsson has been appointed CEO at the Norwegian medtech company Kongsberg Beam Technology. Kerstin Jakobsson has over thirty years of experience in the commercialization of new technologies in the
Careers
As Swedish clinicians treating large numbers of asthma patients, Henrik Ljungberg and Björn Nordlund often spent time reviewing the multiple prescriptions and directives patients received from different providers after flare-ups.
Read the latest issue of our magazine!
No 01 2021 // This Nobel Prize Special issue includes exclusive interviews with Nobel Laureates in Chemistry and Medicine 2020, as well as in-depth articles about their groundbreaking discoveries. Learn more about how the CRISPR/Cas9 genetic scissors is rewriting the code of life and about the fascinating hunt for the hepatitis C virus – a global health success story.
In addition, we take a closer look at the Novo Nordisk Foundation (today among the three biggest foundations in the world), its long history and future plans to further support and promote Danish life sciences. Also, Calliditas Therapeutics shares its winning market entry strategy, a new report by Hadean Ventures highlights the gender gap in life science start-ups, we learn more about Valneva’s role in boosting Sweden’s resilience against future pandemics, and much more!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
NLSDays is the largest Nordic partnering conference dedicated to the life science industry. The 2020 event has been postponed until the 2021 event, April 20-23 2021, delivered digitally. Since its
This event is arranged 2 days in-person and 3 days virtually. This year’s hybrid event enables you to identify, meet and network with leaders across the life science value chain.
Anglonordic is the only life science conference in the UK exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. This one
The largest biotechnology event, BIO International Convention, provides insights and inspiration on major trends affecting the industry. The event attracts big names in biotech, and offers key networking and partnering
The latest research news from the Nordic region
Science Article
Nobel Laureate Harvey J. Alter has focused his scientific career on investigating the causes of transfusion transmitted hepatitis. Doing research and working closely with small groups of patients turned out
Researchers at VTT have developed light and wireless sensors capable of capturing respiration rate, oxygen saturation, heart rate, temperature and even an ECG. If it were possible to monitor the
Danish scientists have showed that regularly eating chocolate might reduce risk of atrial fibrillation (AF), which is an irregular heartbeat. Few people can resist chocolate. That’s why a paper from
With the seventy-five meter-tall Mærsk Tower, the University of Copenhagen has taken an architectural leap towards becoming a spearhead in health and medical sciences. The research tower, designed by C.
The integration of large-scale genomics into the Stockholm region’s healthcare system has helped 1,200 people with rare diseases receive diagnosis. A study from Karolinska Institutet has analyzed the result of
Driven by the curiosity of nature’s secrets, Jennifer Doudna, Nobel Laureate in Chemistry 2020, has devoted her life to the mysteries of biochemistry and cracking a game-changing code. Jennifer Doudna’s
Nordic Life Science
The latest clinical trials
The companies have announced data on the drug candidate lecanemab (BAN2401). The presentations included findings suggesting that lecanemab could be of potential benefit for adults with Down’s syndrome with signs
The research results show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as
Gilead Sciences and Novo Nordisk have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a phase 2b double-blind, placebo-controlled study to investigate the safety and efficacy
Follicum announces that significant progress has been made in the company’s development of new drug treatments for diabetes and other diseases. Within the framework of a preclinical research project, the
Orion Corporation and Bayer are expanding the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in the area of prostate cancer. A new Phase III study
Gedea Biotech has added three Swedish clinics to its NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind
A new survey by SwedenBIO shows that Swedish life science companies are even more confident about future growth compared to pre-COVID. A similar report was published exactly one year ago
Oncorena has announced the Swedish Medical Products Agency’s approval of the Phase 1/2 of First in Patient trial of the compound orellanine in patients with metastatic renal cancer in dialysis.
The first child has been vaccinated in The Gambia with the company’s ETEC vaccine candidate, ETVAX. It is a randomised, placebo-controlled, and double-blind phase IIB study. The study will include
Sign up to our newsletter